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Type 1 diabetes represents an attractive target for human embryonic stem cell (hESC)-based cell replace-
ment therapies. Recently, inNature Biotechnology, Kroon et al. (2008) reported encouraging progress toward
this goal with the development of functional islet-like structures in mice transplanted with hESC-derived
pancreatic endoderm.Type 1 diabetes represents an attractive
target for human embryonic stem cell
(hESC)-based cell replacement therapies.
A lot is known about the biology of insulin
producing b cells, and transplantation
regimens for human islets are well estab-
lished. In theory, if b-like cells or their pre-
cursors could be generated in sufficient
quantities, then it should be possible to
use these in place of cadaveric-derived
islets, the scarcity of which limits the wider
application of islet transplantation as a
treatment option for type 1 diabetes. It is
in this context that we discuss the recent
paper by Kroon et al. (2008) describing
the generation of functional insulin secret-
ing b cells from hESCs. This article com-
plements and extends recent work from
Jiang and colleagues (Jiang et al., 2007)
who also demonstrated that pancreatic
b-like cells derived from hESCs could
lower blood glucose in mice rendered dia-
betic by treatment with the b cell cytotoxic
agent streptozotocin.
Comparing the Kroon and Jiang studies
allows a number of common themes to
be identified. Both methodologies started
with adherent cultures of undifferentiated
hESCs. Some time (2–6 days) after being
passaged, cells were treated with Activin
A. This factor serves as an analog of
the related TGFb family member, nodal,
which is required for gastrulation in the
mouse. In addition to its role as a mesen-
doderm inducer, Activin A also promotes
the emergence of definitive endoderm
(Kubo et al., 2004), the germ layer that
later gives rise to the pancreas. In the pro-
tocol of Kroon et al., 3 days of Activin A
treatment (briefly accompanied by simul-
taneous treatment with Wnt3a on the first
day) was then followed by a similar period
during which Keratinocyte growth factor
(KGF/FGF7) was added to the culture me-300 Cell Stem Cell 2, April 2008 ª2008 Elsevdium. However, comparison with the se-
rum-free protocol of Jiang and colleagues
indicates that neither exogenous Wnt3a
nor KGF was absolutely required for pan-
creatic differentiation.
Following their previously published
protocol, cells in the Kroon et al. study
were subsequently treated with retinoic
acid (RA) for 3 days. This treatment is a
step initially adopted in mouse embryonic
stem cells (ESCs) to pancreas-differen-
tiation protocols (Micallef et al., 2005)
and, like the earlier use of Activin A in
the protocol, represents the application
of embryological findings to ESC culture
technologies (Stafford and Prince, 2002).
The pancreatic cells induced by RA most
likely represent a form of dorsal pancre-
atic endoderm, as studies in mice show
that the development of this tissue is
dependent on RA signaling (Martin et al.,
2005). Concurrent with RA treatment,
Kroon et al. also used a BMP antagonist,
noggin, and a hedgehog signaling path-
way inhibitor, cyclopamine. Again, com-
parison with the work of Jiang et al.
(2007) suggests that the inclusion of these
two inhibitors may not be mandatory for
pancreatic differentiation. It was at this
point that Kroon and colleagues har-
vested cells in preparation for transplan-
tation. In contrast, Jiang et al. continued
their cultures, including both FGF2 and
nicotinamide treatments, because the lat-
ter agent had previously been shown to
induce b cell maturation of human fetal
pancreas (Otonkoski et al., 1993).
In the work of Kroon et al. (2008), mice
were transplanted with cell clumps that
had been differentiated for 11–12 days
and contained cells that coexpressed
NKX6.1, PDX1 (IPF1), and FOXA2, a suite
of transcription factors synonymous with
committed pancreatic progenitors. Byier Inc.monitoring serum human c-peptide levels
over time in the transplant recipients, the
authors were able to track the emergence
of functional b-like cells within developing
grafts. This analysis revealed that the
lengthy interval between transplantation
and the detection of robust glucose-
responsive insulin secretion (as measured
by c-peptide production) reflected the
significant developmental timeline antici-
pated from studies of pancreas ontogeny
(Piper et al., 2004). Once established, the
hESC-derived grafts exhibited the same
dominance in setting the blood glucose
levels as observed previously with trans-
plantation of human fetal islets into mice
(Tuch and Monk, 1991). Also consistent
with previous observations that exocrine
tissue growth in fetal pancreata is not
favored after transplantation (Si et al.,
2001), Kroon et al. observed a high pro-
portion of endocrine cells and a dearth
of exocrine tissue. Finally, they also ob-
served a striking recapitulation of normal
islet morphology and organization in their
grafts, which included the entire spectrum
of hormone expressing cells.
Again, it is instructive to compare and
contrast the transplant data from Kroon
et al. and from Jiang et al. In the Jiang
study, transplantation with fewer (1 3
106 versus 1–2 3 107) and more mature
cells (cultured for up to 20 days versus
11–12 days) into streptozotocin-treated
mice resulted in graft-dependent eugly-
cemia after 7–14 days, but in only 30%
of recipients. Conversely, a higher pro-
portion of recipients in the Kroon study
remained euglycemic after streptozotocin
treatment but required a much longer
period of in vivo graft development. This
finding suggests that the transplanted
material contained more primitive progen-
itors with the ability to generate long-lived
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PreviewsFigure 1. Management of Risks and Benefits Associated with hESC-Based Cell Replacement Therapies
In some instances, the peak incidence of the desired beneficial cell types (broken line; e.g., islet cell precursors) may overlap a period when the risk of teratomas
still persists (high-risk protocol). Future work will require the development of low-risk protocols in which there is a clear temporal separation of risk and benefit
(low-risk protocol). Such low-risk protocols might be employed when purification of the desired end cell may prove detrimental to its function.functional islet-like clusters. It is unclear
whether these clusters arose from single
multipotential progenitors and/or whether
their development required signals from
cotransplanted non-b cells and nonen-
docrine cell types. Similarly, in the case
of the work reported by Jiang and col-
leagues, non-b cell types were also a
notable feature of the ‘‘islet-like clusters’’
that were transplanted. In both instances,
rather than representing a deficiency in
the respective protocols, the presence of
such non-b cell components may turn
out to be critical for the subtle, physiolog-
ical blood glucose regulation required to
give diabetic patients a normal life, free
from long-term complications.
Unfortunately, in addition to the genera-
tion of functional b cells in the vast major-
ity of transplant recipients, Kroon et al.
also observed teratoma formation in a
small number of cases. This outcome
highlights the delicate balance between
the risks and benefits that will need to be
managed in future stem cell replacement
therapies (Figure 1). The most commonly
proposed solution to the general issue of
teratoma formation is to strive for more
highly purified cell populations. This ispredicated on the belief that defined ma-
ture cell populations will be both safer
and therapeutically superior to mixtures
of cells. However, in the clinical setting,
it is the transplantation of the mixture of
different cell types that comprise the
islets that has proven to be effective.
Similarly, as discussed above, it would
not be surprising if the impressive post-
transplantation developmental potential
of hESC-derived pancreatic cells de-
scribed by Kroon et al. depended on ac-
companying non-b cell and/or nonendo-
crine cell types.
In conclusion, it may transpire that the
most efficacious transplanted material
will contain a mixture of cell types (includ-
ing pancreatic and stromal cells, differen-
tiated cells, and progenitors), precluding
the use of cell purification as a means of
eliminating unwanted undifferentiated
hESCs. In this scenario, which may
ultimately not be restricted to hESC-
derived islet cells, the challenge will be
to build on the results of Kroon et al. by
devising protocols that ensure that all
the hESCs in the culture are differentiated
well before cells are harvested for clinical
use.Cell StemREFERENCES
Jiang, W., Shi, Y., Zhao, D., Chen, S., Yong, J.,
Zhang, J., Qing, T., Sun, X., Zhang, P., Ding, M.,
et al. (2007). Cell Res. 17, 333–344.
Kroon, E., Martinson, L.A., Kadoya, K., Bang, A.G.,
Kelly, O.G., Eliazer, S., Young, H., Richardson, M.,
Smart, N.G., Cunningham, J., et al. (2008). Nat.
Biotechnol., in press. Published online February
20, 2008. 10.1038/nbt1393.
Kubo, A., Shinozaki, K., Shannon, J.M., Kouskoff,
V., Kennedy, M., Woo, S., Fehling, H.J., and Keller,
G. (2004). Development 131, 1651–1662.
Martin, M., Gallego-Llamas, J., Ribes, V., Kedinger,
M., Niederreither, K., Chambon, P., Dolle, P., and
Gradwohl, G. (2005). Dev. Biol. 284, 399–411.
Micallef, S.J., Janes, M.E., Knezevic, K., Davis,
R.P., Elefanty, A.G., and Stanley, E.G. (2005).
Diabetes 54, 301–305.
Otonkoski, T., Beattie, G.M., Mally, M.I., Ricordi, C.,
and Hayek, A. (1993). J. Clin. Invest. 92, 1459–1466.
Piper, K., Brickwood, S., Turnpenny, L.W.,
Cameron, I.T., Ball, S.G., Wilson, D.I., and Hanley,
N.A. (2004). J. Endocrinol. 181, 11–23.
Si, Z., Tuch, B.E., and Walsh, D.A. (2001). Cells
Tissues Organs 168, 147–157.
Stafford, D., and Prince, V.E. (2002). Curr. Biol. 12,
1215–1220.
Tuch, B.E., and Monk, R.S. (1991). Transplantation
51, 1156–1160.Cell 2, April 2008 ª2008 Elsevier Inc. 301
